Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 5 · below the Ichimoku cloud · RSI 34 · MACD above its signal · at its 52-week low
None of the 29 investors followed here reported a position in PKTX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PKTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for PKTX.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 65.0 | -31.3 | -32.4 | 17.4 | 6.5 | -11.3 | -98.0 | 100.0 | 0.0 | -50.0 | −98.3% | ||
| 2025 | -5.0 | 42.1 | -10.4 | -17.4 | -9.7 | -3.7 | -37.9 | 32.2 | -23.0 | 33.1 | -7.1 | -11.8 | −40.0% |
| 2024 | -21.1 | 6.7 | 23.7 | -19.2 | -11.3 | -29.6 | 41.0 | 0.0 | -24.1 | -23.4 | 8.5 | 12.4 | −47.4% |
| 2023 | 5.3 | -10.7 | 16.0 | 1.7 | -27.5 | 13.7 | -9.6 | 36.4 | -20.0 | -31.3 | 5.3 | 9.3 | −28.6% |
| 2022 | -31.7 | -10.7 | -9.8 | -9.1 | -40.0 | 16.7 | 5.1 | 0.9 | 4.3 | -8.1 | -15.6 | -11.3 | −73.4% |
| 2021 | 33.3 | 6.5 | 45.8 | 7.3 | -34.4 | 4.0 | -20.0 | 23.9 | -6.0 | -28.7 | -10.0 | 11.5 | +1.0% |
| 2020 | 97.8 | 11.1 | -22.5 | -36.8 | -5.6 | 8.1 | -10.0 | -11.1 | 37.4 | -9.0 | -9.5 | 9.4 | +8.8% |
| 2019 | 23.9 | -28.6 | 22.6 | 22.6 | 54.7 | 43.8 | 0.0 | -5.3 | -49.7 | -9.0 | 7.1 | -6.7 | +28.2% |
| 2018 | 15.8 | -12.6 | -1.7 | -25.9 | 74.4 | 33.3 | -20.0 | 43.8 | 0.0 | -39.1 | 14.3 | -11.2 | +21.8% |
| 2017 | 35.6 | 62.4 | -16.7 | -26.5 | -9.0 | 11.4 | -27.5 | 27.8 | -10.1 | 0.0 | 9.5 | -14.1 | +7.0% |
| 2016 | -8.4 | -14.2 | -18.2 | 41.3 | 11.5 | -8.3 | -3.4 | -13.2 | 35.8 | -21.8 | -1.7 | -4.2 | −22.1% |
| 2015 | -18.6 | 19.9 | 138.2 | -10.0 | -16.7 | -11.7 | -21.5 | 3.9 | -16.7 | 103.4 | -1.7 | -22.2 | +62.8% |
| 2014 | 14.3 | -14.0 | 27.9 | -20.5 | -32.9 | 38.3 | -0.6 | -29.1 | 24.0 | -3.5 | 75.2 | -10.4 | +22.9% |
| 2013 | -6.8 | 28.2 | 24.1 | -14.3 | 0.0 | 33.3 | -25.0 | 0.0 | 19.3 | -21.8 | 185.7 | -12.5 | +196.6% |
| 2012 | -10.0 | 11.1 | -22.0 | 26.9 | -28.3 | -12.0 | 52.0 | -6.3 | -15.7 | -13.3 | -46.2 | 68.6 | −41.0% |
| 2011 | -12.7 | -47.3 | 20.7 | 28.6 | -0.4 | -33.0 | -7.0 | -24.7 | 19.0 | 28.0 | -37.5 | 0.0 | −68.3% |
| 2010 | 25.0 | 8.0 | -16.7 | 0.0 | 33.3 | -20.8 | -5.3 | -11.1 | -12.6 | -21.3 | 9.1 | 5.0 | −21.2% |
| 2009 | -20.7 | 4.3 | -16.7 | 0.0 | 0.0 | 0.0 | 80.0 | -22.2 | -25.0 | -21.0 | 2.4 | -5.9 | −44.8% |
| 2008 | -6.2 | 203.3 | -14.3 | -17.9 | 3.1 | -12.1 | 0.0 | 3.4 | -23.3 | -34.8 | 16.7 | -17.1 | −9.4% |
| 2007 | -8.7 | 2.4 | -11.6 | -10.5 | 11.8 | 5.3 | -5.0 | -15.8 | -23.4 | -51.0 | 33.3 | 0.0 | −65.2% |
No analyst coverage for this instrument.
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications, such as targeted health care solutions, as well as AAGPs are used in ophthalmology, dermatology, transplants, and biomanufacturing areas. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.
No recent headlines.